STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[SCHEDULE 13G/A] CNBX Pharmaceuticals Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

CNBX Pharmaceuticals (CNBX): Schedule 13G/A Amendment No. 6 filed by 3i, LP, 3i Management LLC, and Maier Joshua Tarlow reports beneficial ownership of 80,865,244 shares, representing 9.99% of CNBX common stock.

The position includes 24,600,000 shares held and 56,265,244 shares issuable upon conversion of a senior secured convertible note, subject to a 9.99% beneficial ownership limitation (the “Blocker”). CNBX had 753,196,666 shares outstanding as of September 30, 2025.

The reporting persons indicate shared voting and dispositive power over 80,865,244 shares and no sole power. They certify the securities are not held for the purpose of changing or influencing control of the issuer.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: As more fully described in Item 4 of this Amendment No. 6 to Statement on Schedule 13G (''Amendment No. 6''), such shares and percentage are based on 753,196,666 shares of common stock, par value $0.0001 per share, of the issuer (the ''Common Stock'') outstanding as of September 30, 2025, as verified with the issuer. Beneficial ownership consists of 24,600,000 shares of Common Stock held directly by the reporting person and 56,265,244 shares of Common Stock issuable upon conversion of a senior secured convertible note (the ''Note'') held directly by the reporting person, which conversion is subject to a 9.99% beneficial ownership limitation provision (the ''Blocker'').


SCHEDULE 13G




Comment for Type of Reporting Person: As more fully described in Item 4 of this Amendment No. 6, such shares and percentage are based on 753,196,666 shares of Common Stock outstanding as of September 30, 2025, as verified with the issuer. Beneficial ownership consists of 24,600,000 shares of Common Stock held indirectly by the reporting person and 56,265,244 shares of Common Stock issuable upon conversion of the Note held indirectly by the reporting person, which conversion is subject to a 9.99% Blocker.


SCHEDULE 13G




Comment for Type of Reporting Person: As more fully described in Item 4 of this Amendment No. 6, such shares and percentage are based on 753,196,666 shares of Common Stock outstanding as September 30, 2025, as verified with the issuer. Beneficial ownership consists of 24,600,000 shares of Common Stock held indirectly by the reporting person and 56,265,244 shares of Common Stock issuable upon conversion of the Note held indirectly by the reporting person, which conversion is subject to a 9.99% Blocker.


SCHEDULE 13G



3i, LP
Signature:/s/ 3i, LP
Name/Title:Maier Joshua Tarlow, Manager of 3i Management LLC, General Partner of 3i, LP
Date:11/10/2025
3i Management LLC
Signature:/s/ 3i Management LLC
Name/Title:Maier Joshua Tarlow, Manager
Date:11/10/2025
Maier Joshua Tarlow
Signature:/s/ Maier Joshua Tarlow
Name/Title:Maier Joshua Tarlow
Date:11/10/2025

Comments accompanying signature: LIST OF EXHIBITS Exhibit No. 1 - Joint Filing Agreement, dated March 6, 2023 (incorporated by reference to Exhibit 1 to the Schedule 13G filed by the Reporting Persons with the SEC on March 6, 2023).

FAQ

Who filed this Schedule 13G/A for CNBX?

The filing was made by 3i, LP, 3i Management LLC, and Maier Joshua Tarlow as reporting persons.

How many CNBX shares do the reporting persons beneficially own?

They report 80,865,244 shares beneficially owned.

What percentage of CNBX does this represent?

The filing states ownership of 9.99% of the class.

What is the composition of the reported CNBX position?

It includes 24,600,000 shares held and 56,265,244 shares issuable upon conversion of a senior secured convertible note.

Is there a beneficial ownership cap affecting conversions?

Yes. A 9.99% Blocker limits conversions that would push ownership above 9.99%.

How many CNBX shares were outstanding at the reference date?

There were 753,196,666 shares outstanding as of September 30, 2025.

Do the reporting persons have voting and dispositive power over the shares?

They report shared voting and shared dispositive power over 80,865,244 shares and no sole power.
CNBX Pharms

OTC:CNBX

CNBX Rankings

CNBX Latest News

CNBX Stock Data

27.75k
91.79M
0.78%
13.21%
Biotechnology
Healthcare
Link
United States
Bethesda